DBV Technologies (DBVT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.35 (-1.28%), Market cap $1.10B, 52-week low–high $7.74 ~ $24.54.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health
Financial statements, price targets, institutional (13F) holdings and related news for DBV Technologies are updated in real time on BlackAll Trade.
DBV Technologies trades at $12.35 (-1.28%). Real-time quotes and charts are available on BlackAll Trade.
DBV Technologies has a market cap of about $1.10B.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Pea